McKesson (MCK) closed at $488.78 in the latest trading session, marking a -1.95% move from the prior day. This change lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow saw an upswing of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Robert W. Baird analyst Eric Coldwell downgraded the rating on McKesson (MCK – Research Report) to a Hold today, setting a price target ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Deutsche Bank analyst George Hill maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $579.00.

McKesson Corp., Cencora Inc. and Cardinal Health Inc. are among firms that have offered to acquire the company, according to the people. Florida Cancer Specialists may be valued at more than $3 ...

Shares of McKesson (MCK) fell sharply on Thursday ... Meanwhile, Zimmer Biomet (ZBH) shares sank after the medical products company warned that issues with an enterprise resource system would ...

McKesson has signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. “This transaction marks an important ...

Data by YCharts That said, as past returns are not indicative of future performances, I'll use this article to explain why McKesson has ... company focuses on medical supply distribution services.

McKesson shares plunged after the medical products distributor announced plans to sell its Canada-based Rexall and Well.ca businesses. Dollar Tree shares moved higher, clawing back some of the ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...